Richmond Pharmacology Celebrates 10 Years at the Henley Royal Regatta

Posted:
4
August 2011

Richmond Pharmacology Ltd (RPL) is proud to announce that it recently celebrated its 10th anniversary in style with a quintessentially British day on the river at this year�s Henley Royal Regatta.  

The Henley Royal Regatta has been held annually since 1839 and remains one of Britain s most prestigious sporting events, and as such was a fitting place to hold this esteemed celebration.The day started off with an official welcome by RPL s co-founder and CEO, Dr Jorg Taubel, followed by a morning presentation by guest speaker, Dr Tony Soteriou, Deputy Director, Head of NHS Research Infrastructure and Industry R&D Relations from the Department of Health, looking at new initiatives to simplify the regulatory process for clinical research conducted in the United Kingdom.

After the morning presentation guests attended the prestigious Fawley Meadows Restaurant to relax and enjoy the afternoon s festivities.

Richmond Pharmacology was co-founded in August 2001 by RPL s three Executive Directors Dr Ulrike Lorch, Dr Radivoj Arezina and Dr J rg T ubel, and first opened at the Atkinson Morely Hospital in Wimbledon.  10 years on, now based in two of the UK s largest acute NHS teaching hospitals, RPL has undergone steady expansion and has since become one of Europe s leading full-service specialist early phase CROs. The first to obtain MHRA standard and supplementary accreditation for two hospital based clinical trial units coupled with its supreme expertise gained from over 500 early phase studies carried out to date, RPL is proud to be celebrating 10 years of clinical excellence, still leading the way as the experts in the field of early phase clinical research!

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more